November 18, 2002
The idea that a planned structured treatment interruption could have advantages has been around for many years. The theory behind this is that by regularly stopping drugs and taking a break, a patient's exposure to the drugs will be lowered and the chance of developing side effects and toxicities will also be lessened.
In addition, it has been suggested that by stopping the drugs and allowing the immune system a chance "to see the virus" as it rebounds could lead to natural control of HIV in the long term. However, so far this has not been shown to be the case in the clinical setting. Dr. Yeni pointed out the problems of structured treatment interruptions in such a situation, especially in patients who have low CD4 counts. In addition, some patients have had very dramatic falls in their CD4 counts after only a short time off therapy, and some patients even develop a seroconversion-like illness secondary to viral rebound.
In the setting of acute infection, animal studies have suggested that structured treatment interruptions immediately after infection may lead to control of HIV infection. Although there are case reports of this occurring in clinical practice, no data has been presented from a clinical trial of such a situation.
The final situation in which a structured treatment interruption is used is in patients with multi-resistant virus with little chance of rescue with available drugs. Structured treatment interruption in such a position will remove drug pressure for the virus to have continuing resistance and, hopefully, will lead to a better response when drugs are introduced. This is the subject of many ongoing clinical studies, such as the MRC Optima study.
However, in clinical studies, there is little data to support this, apart from the French GIGA HAART study in which patients who had been on failing regimens underwent an eight-week structured treatment interruption, and were then treated with a multiple-drug therapy, had a better response than those who switched directly to multiple-drug therapy. These results were maintained out to 48 weeks. The danger of a structured interruption in such a setting is the possible fall in CD4 count, which may take several months to recover, despite the introduction of antiretroviral therapy, and the increased viral load, which has been noted to be a factor of disease progression in many studies.
|Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.|
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.